TheTechno Optimist.

LeqvioNovartis—Leqvio (inclisiran) Q2 2026 revenue reaches $480M, up 59% year-over-year, with peak sales target of $4-5BItvisma (onasemnogene abeparvovec-brve)Novartis—EU approves Itvisma for SMA in children 2+ and adultsDel-zota (delpacibart zotadirsen)Novartis—FDA accepts BLA for del-zota in DMD44 with priority reviewLeqvioNovartis—FDA updates Leqvio label to recognize cardiovascular outcomes benefits

Leqvio

by NovartisCH

Expand cholesterol management with convenience and efficacy of twice-yearly siRNA therapy.

DeployStage 4 of 5

FDA approved for ASCVD, FH, and pediatric 12+; ORION-4 and VICTORION-2-PREVENT reading out 2027.

Updated 19 Aug 2026Checked 11 Oct0 updates this week

Milestones

Next · ORION-4 cardiovascular outcomes trial readout
  1. FDA approval for ASCVD and heterozygous familial hypercholesterolemiaDec 2021Complete.
  2. FDA approval for HoFH and HeFH patients ages 12+12 Feb 2026Complete.
  3. Leqvio Q2 2026 revenue $480M (+59% YoY)Q2 2026Complete.
  4. FDA label update to include cardiovascular outcomes language19 Aug 2026Complete.
  5. ORION-4 cardiovascular outcomes trial readoutTarget 2027Not yet reached.

Most important updates

Upcoming

  1. 2027ORION-4 cardiovascular outcomes trial readout (next)
  2. 2027VICTORION-2-PREVENT secondary prevention trial results
Primer